These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 27003023

  • 1. Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008-2012).
    Woolcock AD, Bugbee AC, Creevy KE.
    J Am Vet Med Assoc; 2016 Apr 01; 248(7):814-21. PubMed ID: 27003023
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Laboratory assessment of trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism.
    Arenas Bermejo C, Pérez Alenza D, García San José P, Llauet L, Pérez-López L, Melián C, C Feldman E.
    J Vet Intern Med; 2020 Jul 01; 34(4):1413-1422. PubMed ID: 32533623
    [Abstract] [Full Text] [Related]

  • 7. Cortisol, aldosterone, cortisol precursor, androgen and endogenous ACTH concentrations in dogs with pituitary-dependant hyperadrenocorticism treated with trilostane.
    Sieber-Ruckstuhl NS, Boretti FS, Wenger M, Maser-Gluth C, Reusch CE.
    Domest Anim Endocrinol; 2006 Jul 01; 31(1):63-75. PubMed ID: 16233969
    [Abstract] [Full Text] [Related]

  • 8. Comparison of two treatment regimens with trilostane in dogs with pituitary-dependent hyperadrenocorticism.
    Braun C, Boretti FS, Reusch CE, Sieber-Ruckstuhl NS.
    Schweiz Arch Tierheilkd; 2013 Oct 01; 155(10):551-8. PubMed ID: 24091230
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Evaluation of 2 trilostane protocols for the treatment of canine pituitary-dependent hyperadrenocorticism: twice daily versus once daily.
    Arenas C, Melián C, Pérez-Alenza MD.
    J Vet Intern Med; 2013 Oct 01; 27(6):1478-85. PubMed ID: 24118316
    [Abstract] [Full Text] [Related]

  • 11. Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.
    Griebsch C, Lehnert C, Williams GJ, Failing K, Neiger R.
    J Vet Intern Med; 2014 Oct 01; 28(1):160-5. PubMed ID: 24341822
    [Abstract] [Full Text] [Related]

  • 12. Serum concentrations of cortisol and cortisone in healthy dogs and dogs with pituitary-dependent hyperadrenocorticism treated with trilostane.
    Sieber-Ruckstuhl NS, Boretti FS, Wenger M, Maser-Gluth C, Reusch CE.
    Vet Rec; 2008 Oct 18; 163(16):477-81. PubMed ID: 18931355
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of low- and high-dose trilostane treatment in dogs (< 5 kg) with pituitary-dependent hyperadrenocorticism.
    Cho KD, Kang JH, Chang D, Na KJ, Yang MP.
    J Vet Intern Med; 2013 Oct 18; 27(1):91-8. PubMed ID: 23167780
    [Abstract] [Full Text] [Related]

  • 14. Association between post-ACTH cortisol and trilostane dosage in dogs with pituitary-dependent hypercortisolism.
    Gouvêa FN, Vargas AM, Guimarães EC, Crivellenti LZ, Pennacchi CS, de Cerqueira HDB, Branco LO, Reis NS, Borin-Crivellenti S.
    Domest Anim Endocrinol; 2024 Oct 18; 89():106871. PubMed ID: 39032188
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism.
    Vaughan MA, Feldman EC, Hoar BR, Nelson RW.
    J Am Vet Med Assoc; 2008 May 01; 232(9):1321-8. PubMed ID: 18447776
    [Abstract] [Full Text] [Related]

  • 16. Effect of trilostane and mitotane on aldosterone secretory reserve in dogs with pituitary-dependent hyperadrenocorticism.
    Reid LE, Behrend EN, Martin LG, Kemppainen RJ, Ward CR, Lurye JC, Donovan TC, Lee HP.
    J Vet Intern Med; 2014 May 01; 28(2):443-50. PubMed ID: 24400747
    [Abstract] [Full Text] [Related]

  • 17. Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment.
    Boretti FS, Holzthüm J, Reusch CE, Sieber-Ruckstuhl NS.
    Schweiz Arch Tierheilkd; 2016 Sep 01; 158(9):631-638. PubMed ID: 27655162
    [Abstract] [Full Text] [Related]

  • 18. Update on the use of trilostane in dogs.
    Lemetayer J, Blois S.
    Can Vet J; 2018 Apr 01; 59(4):397-407. PubMed ID: 29606727
    [Abstract] [Full Text] [Related]

  • 19. Carbenoxolone Disodium Treatment for Canine Pituitary-Dependent Hyperadrenocorticism.
    Teshima T, Matsumoto H, Okusa T, Uchiyama R, Koyama H.
    PLoS One; 2016 Apr 01; 11(11):e0166267. PubMed ID: 27824928
    [Abstract] [Full Text] [Related]

  • 20. Effect of trilostane on serum concentrations of aldosterone, cortisol, and potassium in dogs with pituitary-dependent hyperadrenocorticism.
    Wenger M, Sieber-Ruckstuhl NS, Müller C, Reusch CE.
    Am J Vet Res; 2004 Sep 01; 65(9):1245-50. PubMed ID: 15478772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.